Sponsors (50)
The bill provides meaningful, multi-year federal investment to improve type 1 diabetes research and care at the cost of roughly $800 million over five years to the federal budget.
People with type 1 diabetes gain sustained federal funding of $160 million per year (2026–2030) for research, care, and programs, supporting improved treatments and health outcomes.
Researchers, hospitals, and health systems receive predictable multi-year funding, enabling longer-term studies, program planning, and improved capacity to translate research into care for type 1 diabetes.
Taxpayers and the federal budget bear about $800 million in new spending over five years, which could crowd out other priorities or increase deficits if not offset.
Based on analysis of 2 sections of legislative text.
Authorizes $160 million annually for FY2026–FY2030 for the Special Diabetes Programs for Type 1 diabetes, with funds available until expended.
Introduced September 18, 2025 by Diana DeGette · Last progress September 18, 2025
Authorizes $160 million per year for the Special Diabetes Programs for Type 1 diabetes for each fiscal year 2026 through 2030, with those funds to remain available until expended. The change amends the Public Health Service Act to add this authorization and adjusts prior statute text to accommodate the new funding line. This is an authorization of spending levels; actual payments require future appropriations. The authorization covers five fiscal years (2026–2030) totaling $800 million in authorized funding, supporting Type 1 diabetes research and related programs.